The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Open accessAbstract
BACKGROUND: alteration. Data are needed to confirm and expand on the findings of the phase 2 study. METHODS: alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). We randomly assigned the patients in a 2:1 ratio to receive oral rucaparib (600 mg twice daily) or a physician's choice control (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]). The primary outcome was the median duration of imaging-based progression-free survival according to independent review. RESULTS: alteration. At 62 months, the duration of imaging-based progression-free survival was significantly longer in the rucaparib group than in the control group, both in the BRCA subgroup (median, 11.2 months and 6.4 months, respectively; hazard ratio, 0.50; 95% confidence interval [CI], 0.36 to 0.69) and in the intention-to-treat group (median, 10.2 months and 6.4 months, respectively; hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001 for both comparisons). In an exploratory analysis in the ATM subgroup, the median duration of imaging-based progression-free survival was 8.1 months in the rucaparib group and 6.8 months in the control group (hazard ratio, 0.95; 95% CI, 0.59 to 1.52). The most frequent adverse events with rucaparib were fatigue and nausea. CONCLUSIONS: alteration. (Funded by Clovis Oncology; TRITON3 ClinicalTrials.gov number, NCT02975934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 3 randomized trials PROfound (NCT02987543), and TRITON-3 (NCT02975934), treatment with PARP inhibitors was favored in both chemotherapy-naïve patients and those who had received prior taxane-based chemotherapy [57, 58].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an exploratory analysis of a subgroup of TRITON-3 evaluating patients with BRCA alterations, the median PFS with rucaparib (11.2 months) was longer than with docetaxel (6.4 months; p < 0.001) [57].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationAshworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Flagged first, then by citations
Research works printed but not linked: 2
- Rubraca (rucaparib) tablets. Boulder, CO: Clovis Oncology, 2022 (package insert).
- Lynparza (olaparib) tablets. Wilmington, DE: AstraZeneca Pharmaceuticals, 2022 (package insert).
Cited by
Sorted by citations
Items 401–452 of 452
Baskarane, H., Jain, R., Divakar, M. K., Seth, A., Nayak, B., Bakhshi, S., Sahoo, R. K., Kumar, A., Sharma, A., Kaushal, S., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag059
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors
蔡, 江. (2026) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2026.141008
Zeng, S., Xu, Z., Xing, S., Zhang, Y., Liu, J., Zhang, Y., & Liu, Q. (2026) · European journal of medical research · doi:10.1186/s40001-026-04029-0
Shi, X., Rifai, S., Meher, Z., & Hussain, A. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001230
Yan, H., Mao, A., Li, D., Fu, G., Pérez‐Baena, M. J., Jiménez‐Navas, A., Wang, D., Hong, R., Cai, W., Pérez‐Losada, J., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218447
Kohli, M., Wang, L., Tan, A. C., Fadlullah, M. Z. H., Shankar, A., Mandrekar, S. J., & Haaland, B. A. (2026) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2026.100486
Chen, Y., Bobek, O. J., Heller, G., Berg, S. A., Tan, A., Zhao, S. G., Galsky, M. D., Rosenberg, J. E., Beltran, H., & McKay, R. R. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00187
Ostrowski, M., Jo, Y., Hardy, T., Gebrael, G., Srivastava, A., Özay, Z. İ., Chehade, C. H., Sayegh, N., Ji, R., Thomas, V. M., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00167
Hoshi-Kadonosawa, Y., Reinhold, W. C., Taniyama, D., Inoue, Y., Luna, A., Kumar, S., Sun, N.-Y., Kim, Y. S., Yin, J. J., Roper, N., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-26-0011
Management of CRPC (Metastatic and Non-metastatic)
Kashyap, L. (2026) · Springer eBooks · doi:10.1007/978-981-95-5945-9_8
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer
Cren, P., Buteau, J. P., Fatema, U., Patel, R., Saraiya, B., Emmett, L., & Fizazi, K. S. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-516658
Self-citationCaramelo, B., García-Berbel, P., Carmen, S. D., Terán, A. K. C., Corrêa, L., Martinez-Villaseñor, L., Sotelo, M., Rojo, F., Gómez‐Román, J., Durán, I., et al. (2026) · Cancers · doi:10.3390/cancers18101614
Decker, B. J., Sisoudiya, S. D., Thornton, J., Cui, C., Harada, T., Solieva, S. O., Madison, R. W., Datta, A., Shi, T., Guintini, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.19.726319
He, R., Xing, Q., Liu, S., Lin, S., Lin, X., & Ye, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1832473
PARP9-mediated PARylation is essential for the cytotoxicity of talazoparib in colorectal cancer
Mei, J., Yang, C., Zhou, Y., Zhang, J., Yue, Z., & Yang, Z. (2026) · Research Connections · doi:10.1093/rescon/vmag079
Advancing metastatic prostate cancer care: best practices and future directions in molecular testing
Castro, E., Chen, J., Lowentritt, B. H., Das, P. M., Dowlati, R., & Olmos, D. (2026) · Prostate International · doi:10.1016/j.prnil.2026.06.002
Allaume, P., Raby, M., Nourieh, M., Lespagnol, A., Tallet, A., Péricart, S., Tantot, J., Lindner, V., Decaussin‐Petrucci, M., Callens, C., et al. (2026) · The French Journal of Urology · doi:10.1016/j.fjurol.2026.103148
Abahssain, H., Sabri, O., Lemaire, A., & Souadka, A. (2026) · Cancers · doi:10.3390/cancers18121949
Bryce, A. H., Nash, P., Roessler, A., & Mandair, D. (2026) · Future Oncology · doi:10.1080/14796694.2026.2681674
Self-citationCompérat, É., Amsberg, G. V., Corrigan, L., Finn, S. P., Kristiansen, G., Minucci, A., Olmos, D., & Roubaud, G. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1874947
Santiago-Sánchez, G. S., Rosato, F., Fabian, K. P., Padget, M. R., Lee, J.-M., Karzai, F. H., Schlom, J., Gulley, J. L., Hamilton, D. H., Lee, J. K., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014518
Miedziarek, C., Caputa, P., Bochyński, H., Zaborowski, M. P., & Nowak‐Markwitz, E. (2026) · Cancers · doi:10.3390/cancers18132157
Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers
Akhoundova, D., Fernández, M. G., Baral, A., Benjak, A., Perry, C., Lubis, D. S. H., Hörtensteiner, L., Hussung, S., Lingg, L., Maletti, S., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01596-7
Genitourinary Cancer: Recent Advances in Diagnosis and Treatment
Zhang, J., & Zimmerman, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-19175-5_20
An evolving arsenal: new hope in fighting advanced prostate cancer
Vanderkamp, E., Parker, J. M., Wakefield, M. R., & Fang, Y. (2026) · Canadian Journal of Urology · doi:10.32604/cju.2026.078273
Huang, Q.-Y., Li, Y., Bi, Y., Zhang, J., Jiang, W., Wang, H., Zhao, J., Yang, H., Shi, X., Jiang, J., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124476
Valle, L., Scobie, M. R., Rowe, K. G., Pritchard, C. C., Montgomery, B., Garraway, I. P., Nickols, N. G., Schoen, M. W., Kishan, A. U., Kelley, M. J., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag265
Swearingen, A., Audu, B. M., Hamidu, A., Mustapha, A., Oguntayo, A. O., Yahya, A., Bello, A. M., Butler, R., Halliday, D., Bowe, S., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag291
Zhong, C., Pang, M., Sun, H., Yang, H., & Mao, Y. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.07.059
Shao, D., Song, Y., Liu, J., Zhao, M., Xie, X., Wei, Z., Han, D., Song, X., Xu, H., Xu, G., et al. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104995
Rodríguez-Olivares, J. L., Pineda, M. M., Beas-Lozano, E. L., Seidman-Sorsby, A., Remolina-Bonilla, Y. A., Gamboa‐Domínguez, A., Weitzel, J. N., Barata, P., Chavarri-Guerra, Y., & Bourlon, M. T. (2026) · ONCOLOGY · doi:10.46883/2026.25921234
Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review
Garcia, C. C., Moryousef, J., Pinthus, J. H., & Leong, D. P. (2026) · Cancers · doi:10.3390/cancers18152465
Garofoli, M., Natalicchio, M. I., Bruno, G., Rosano, A., Maiorano, B. A., Rossetti, S., Scagliarini, S., Incorvaia, L., Formisano, L., Toma, I., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-05086-2
Bitting, R. L., Tseng, C., Giagtzis, A., Wyatt, A. W., McNair, C. M., Kim, H., Halabi, S., & Giri, V. N. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102640
Azad, F., Kevu, E., & Aragon‐Ching, J. B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2722329
Choudhury, A. D., Zhong, C., Xie, W., Kochupurakkal, B. S., Wu, P. I.-F., Riaz, I. B., Liu, R., Yang, D. D., Folefac, E., Lee, D., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0488
Liquid biopsy: a new window on the BRCA genes
Incorvaia, L., Gristina, V., Pepe, F., Russo, T. D. B., Santoni, M., Mujacic, C., Curigliano, G., Malapelle, U., Capoluongo, E. D., & Russo, A. D. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108349
Chen, H., Huang, Z., Zhang, W., Feng, J., Xu, X., Lin, J., Zeng, Z., & Wang, C. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117409
Sereti, E., Axelsson, S. E., Törnell, J., Rehnmark, S., Högberg, M., & Bjartell, A. S. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04946-1
Advancements and future directions in transformative therapies of prostate cancer
Zhao, J., Tang, B., Zeng, H., & Wei, Q. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004322
Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel
Mattana, F., Palesandro, E., Dragonetti, V., Curigliano, G., Tucci, M., & Ceci, F. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103216
Kjer, M. F., Poulsen, M. H., Kjær‐Frifeldt, S., Holt, M. I., Vilstrup, M. H., & Zedan, A. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198453
Jain, R. R., Vasudeva, N., Baskarane, H., Arora, A., Sharma, A., Kumar, A., Haresh, K. P., Kaushal, S., Shamim, S. A., Nayak, B., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108581
Sharaf, B., Al-Rwashdeh, M., Khatib, O. E., Al‐Ibraheem, A., Fara, A. A., Ismail, A., Alkasrawi, H., Abdalla, M., & Jehad, S. (2026) · Cancers · doi:10.3390/cancers18193119
Li, Z., Cao, H., Ye, Z., Wang, B., Li, S., Wu, H., Bai, Z., & Gao, B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1949460
Kitamura, H., Miura, Y., Matsubara, N., Rini, B. I., & Powles, T. B. (2026) · Research Square · doi:10.21203/rs.3.rs-11090721/v1
Gao, X., Garmezy, B., Vuky, J., Shen, J., Sartor, O. A., Sternberg, C. N., Dreicer, R., Hussain, M., Kalebasty, A. R., Percent, I. J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02995
The role of PARP inhibition and HRR alterations in mHSPC: current evidence and future perspectives
Crippa, N., Montelatici, G., Claps, M., Guadalupi, V., Gusmaroli, E., Mascaro, F., Nuzzo, A., Rametta, A., Sciortino, C., Rota, S., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261449096
Liu, Z. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.55363
Zacchi, F., Castro, E., Imbach, K., Rodríguez‐Vida, A., Simonetti, S., Mellado, B., Mir, G., Aguilar, D., Castellano, D., Climent, M. A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04671-5
Self-citationCancer risks associated with BRCA1 and BRCA2 : Overview and management
Breen, K. E., Vashisth, S., & Liu, Y. L. (2026) · Cancer · doi:10.1002/cncr.70635
INIBIDORES DE PARP NO CÂNCER DE PRÓSTATA: AVANÇOS, DESAFIOS E PERSPECTIVAS NA TERAPIA DIRECIONADA
Andrade, L. S. F. A., Neves, M. L. R., & Moura, N. I. V. (2026) · Aurum Editora eBooks · doi:10.63330/cabapsamed2025-009
Metadata
- Authors
- Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nolè, F., Staffurth, J., Redfern, C., Sáez, M. I., Abida, W., Daugaard, G., Heidenreich, A., Krieger, L., Sautois, B., Loehr, A., Despain, D., Heyes, C. A., Watkins, S. P., Chowdhury, S., Ryan, C. J., & Bryce, A. H.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Guy's Hospital (GB)
- University of Minnesota (US)
- ORCID
- Fizazi, Karim
- Piulats, Josep M.
- Reaume, M. Neil
- Ostler, Peter
- McDermott, Ray
- Gingerich, Joel R.
- Pintus, Elias
- Sridhar, Srikala S.
- Bambury, Richard M.
- Emmenegger, Urban
- Lindberg, Henriette
- Morris, David
- Nolè, Franco
- Staffurth, John
- Abida, Wassim
- Daugaard, Gedske
- Heidenreich, Axel
- Krieger, Laurence
- Sautois, Brieuc
- Loehr, Andrea
- Despain, Darrin
- Watkins, Simon P.
- Ryan, Charles J.
- Bryce, Alan H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-02-23
- Volume
- 388
- Issue
- 8
- Pages
- 719-732
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10064172
- OpenAlex
- W4321079951
- Cited by
- 449
- References
- 27
- Citations by year
- 2026: 91 · 2025: 134 · 2024: 139 · 2023: 85
- FWCI
- 82.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion, other-oa)
- Funders
- Clovis Oncology
- National Cancer Institute (P30-CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- rucaparib, metastatic prostate cancer, PARP inhibitors, BRCA mutations, ATM mutations, progression-free survival, androgen receptor pathway inhibitors, docetaxel, abiraterone, enzalutamide, PARP inhibitor resistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Docetaxel, Progression-Free Survival, Androgen Antagonists, Androstenes, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Indoles, Male, Nitriles, Phenylthiohydantoin, Disease Progression, Genes, BRCA1, Genes, BRCA2, Ataxia Telangiectasia Mutated Proteins, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
